276 related articles for article (PubMed ID: 1658705)
21. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
Alexander WS; Bernard O; Cory S; Adams JM
Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
[TBL] [Abstract][Full Text] [Related]
22. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
23. Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.
Kroese ED; Dortant PM; van Steeg H; van Oostrom CT; van der Houven van Oordt CW; van Kranen HJ; de Vries A; Wester PW; van Kreijl CF
Carcinogenesis; 1997 May; 18(5):975-80. PubMed ID: 9163683
[TBL] [Abstract][Full Text] [Related]
24. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
25. Ig heavy chain protein controls B cell development by regulating germ-line transcription and retargeting V(D)J recombination.
Schlissel MS; Morrow T
J Immunol; 1994 Aug; 153(4):1645-57. PubMed ID: 8046237
[TBL] [Abstract][Full Text] [Related]
26. Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues.
Roh M; Kim J; Song C; Wills M; Abdulkadir SA
Genesis; 2006 Oct; 44(10):447-53. PubMed ID: 17013838
[TBL] [Abstract][Full Text] [Related]
27. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
28. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.
van Lohuizen M; Verbeek S; Krimpenfort P; Domen J; Saris C; Radaszkiewicz T; Berns A
Cell; 1989 Feb; 56(4):673-82. PubMed ID: 2537153
[TBL] [Abstract][Full Text] [Related]
29. Leukaemogenesis by the delta Mo + SV Moloney murine leukaemia virus (M-MuLV) variant in E mu pim-1 transgenic mice: high frequency of recombination with a solo endogenous M-MuLV LTR in vivo.
Suchman EL; Pattengale PK; Fan H
J Gen Virol; 1995 Feb; 76 ( Pt 2)():347-56. PubMed ID: 7844555
[TBL] [Abstract][Full Text] [Related]
30. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.
Lovec H; Grzeschiczek A; Kowalski MB; Möröy T
EMBO J; 1994 Aug; 13(15):3487-95. PubMed ID: 8062825
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
32. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras.
Breuer M; Wientjens E; Verbeek S; Slebos R; Berns A
Cancer Res; 1991 Feb; 51(3):958-63. PubMed ID: 1988138
[TBL] [Abstract][Full Text] [Related]
33. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
34. Influence of a V kappa 8 L chain transgene on endogenous rearrangements and the immune response to the HA(Sb) determinant on influenza virus.
Carmack CE; Camper SA; Mackle JJ; Gerhard WU; Weigert MG
J Immunol; 1991 Sep; 147(6):2024-33. PubMed ID: 1909739
[TBL] [Abstract][Full Text] [Related]
35. Alterations in pim-1 and c-myc expression associated with sodium butyrate-induced growth factor dependency in autonomous rat Nb2 lymphoma cells.
Buckley AR; Leff MA; Buckley DJ; Magnuson NS; de Jong G; Gout PW
Cell Growth Differ; 1996 Dec; 7(12):1713-21. PubMed ID: 8959340
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc.
Karsunky H; Geisen C; Schmidt T; Haas K; Zevnik B; Gau E; Möröy T
Oncogene; 1999 Dec; 18(54):7816-24. PubMed ID: 10618723
[TBL] [Abstract][Full Text] [Related]
37. Cell populations during tumorigenesis in Eu-myc transgenic mice.
Sidman CL; Shaffer DJ; Jacobsen K; Vargas SR; Osmond DG
Leukemia; 1993 Jun; 7(6):887-95. PubMed ID: 8501983
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
39. Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/c-myc and Ig/tax genes.
Benvenisty N; Ornitz DM; Bennett GL; Sahagan BG; Kuo A; Cardiff RD; Leder P
Oncogene; 1992 Dec; 7(12):2399-405. PubMed ID: 1461648
[TBL] [Abstract][Full Text] [Related]
40. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
